{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:21:08Z","timestamp":1780420868564,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20251849"],"award-info":[{"award-number":["BK20251849"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20221287"],"award-info":[{"award-number":["BK20221287"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Social Development Foundation of Zhenjiang","award":["SH2025073"],"award-info":[{"award-number":["SH2025073"]}]},{"name":"Social Development Foundation of Zhenjiang","award":["SH2024029"],"award-info":[{"award-number":["SH2024029"]}]},{"name":"Social Development Foundation of Zhenjiang","award":["SH2023022"],"award-info":[{"award-number":["SH2023022"]}]},{"name":"Social Development Foundation of Zhenjiang","award":["SH2024001"],"award-info":[{"award-number":["SH2024001"]}]},{"name":"Medical Education Collaborative Innovation Fund of Jiangsu University","award":["JDYY2023021"],"award-info":[{"award-number":["JDYY2023021"]}]},{"name":"Medical Education Collaborative Innovation Fund of Jiangsu University","award":["JDY2023008"],"award-info":[{"award-number":["JDY2023008"]}]},{"name":"Horizontal Project from Jichuan Pharmaceutical Group Co., Ltd.","award":["JC-2023-002"],"award-info":[{"award-number":["JC-2023-002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81900166"],"award-info":[{"award-number":["81900166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970118"],"award-info":[{"award-number":["81970118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Project of Jiangsu Commission of Health","award":["M2022123"],"award-info":[{"award-number":["M2022123"]}]},{"name":"Zhenjiang Clinical Research Center of Hematology","award":["SS2018009"],"award-info":[{"award-number":["SS2018009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-41978-2","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:55:18Z","timestamp":1772438118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies"],"prefix":"10.1038","volume":"16","author":[{"given":"Zi-jun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-mei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing\u2011dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"41978_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"41978_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.Cd-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 8, 1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0367 (2018).","journal-title":"Cancer Discov."},{"key":"41978_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Sci. (New York N Y). 359, 1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060 (2018).","journal-title":"Sci. (New York N Y)"},{"key":"41978_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A., Ribas, A. & Primary Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707\u2013723. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017 (2017).","journal-title":"Cell"},{"key":"41978_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466 (2010).","journal-title":"N. Engl. J. Med."},{"key":"41978_CR6","doi-asserted-by":"publisher","first-page":"1323914","DOI":"10.3389\/fonc.2024.1323914","volume":"14","author":"P Pophali","year":"2024","unstructured":"Pophali, P., Varela, J. C. & Rosenblatt, J. Immune checkpoint blockade in hematological malignancies: current state and future potential. Front. Oncol. 14, 1323914. https:\/\/doi.org\/10.3389\/fonc.2024.1323914 (2024).","journal-title":"Front. Oncol."},{"key":"41978_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Immunogenomic Landscape of Hematological Malignancies. Cancer cell. 38, 380\u2013399e313. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.002 (2020).","journal-title":"Cancer cell."},{"key":"41978_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.Can-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. STK11\/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 76, 999\u20131008. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1439 (2016).","journal-title":"Cancer Res."},{"key":"41978_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/2326-6066.Cir-18-0489","volume":"7","author":"W Xu","year":"2019","unstructured":"Xu, W. et al. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunol. Res. 7, 1497\u20131510. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0489 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"41978_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","volume":"7","author":"N Li","year":"2017","unstructured":"Li, N. et al. Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis. Sci. Rep. 7, 1485. https:\/\/doi.org\/10.1038\/s41598-017-01411-1 (2017).","journal-title":"Sci. Rep."},{"key":"41978_CR11","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.2147\/jir.S458651","volume":"17","author":"H Xie","year":"2024","unstructured":"Xie, H. et al. VISTA Deficiency Exacerbates the Development of Pulmonary Fibrosis by Promoting Th17 Differentiation. J. Inflamm. Res. 17, 3983\u20133999. https:\/\/doi.org\/10.2147\/jir.S458651 (2024).","journal-title":"J. Inflamm. Res."},{"key":"41978_CR12","doi-asserted-by":"publisher","first-page":"821649","DOI":"10.3389\/fcell.2022.821649","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis. Front. cell. Dev. biology. 10, 821649. https:\/\/doi.org\/10.3389\/fcell.2022.821649 (2022).","journal-title":"Front. cell. Dev. biology"},{"key":"41978_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","volume":"13","author":"X Huang","year":"2020","unstructured":"Huang, X. et al. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J. Hematol. Oncol. 13, 83. https:\/\/doi.org\/10.1186\/s13045-020-00917-y (2020).","journal-title":"J. Hematol. Oncol."},{"key":"41978_CR14","doi-asserted-by":"publisher","first-page":"20230866","DOI":"10.1515\/med-2023-0866","volume":"18","author":"R Ren","year":"2023","unstructured":"Ren, R., Chang, X., Chen, C., Yu, H. & Han, L. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature. Open. Med. (Wars). 18, 20230866. https:\/\/doi.org\/10.1515\/med-2023-0866 (2023).","journal-title":"Open. Med. (Wars)"},{"key":"41978_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando, J. et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A. 116, 1692\u20131697. https:\/\/doi.org\/10.1073\/pnas.1811067116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"41978_CR16","doi-asserted-by":"publisher","first-page":"e1469594","DOI":"10.1080\/2162402x.2018.1469594","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology 7, e1469594. https:\/\/doi.org\/10.1080\/2162402x.2018.1469594 (2018).","journal-title":"Oncoimmunology"},{"key":"41978_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/2326-6066.Cir-18-0507","volume":"7","author":"J Deng","year":"2019","unstructured":"Deng, J. et al. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunol. Res. 7, 1079\u20131090. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0507 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"41978_CR18","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2326-6066.Cir-23-0117","volume":"11","author":"B Wang","year":"2023","unstructured":"Wang, B. et al. Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant. Cancer Immunol. Res. 11, 1656\u20131670. https:\/\/doi.org\/10.1158\/2326-6066.Cir-23-0117 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"41978_CR19","doi-asserted-by":"publisher","first-page":"114260","DOI":"10.1016\/j.celrep.2024.114260","volume":"43","author":"ME Bordeleau","year":"2024","unstructured":"Bordeleau, M. E. et al. Immunotherapeutic targeting of surfaceome heterogeneity in AML. Cell. Rep. 43, 114260. https:\/\/doi.org\/10.1016\/j.celrep.2024.114260 (2024).","journal-title":"Cell. Rep."},{"key":"41978_CR20","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1002\/cam4.5409","volume":"12","author":"K Yao","year":"2023","unstructured":"Yao, K., Zhou, E., Schaafsma, E., Zhang, B. & Cheng, C. Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes. Cancer Med. 12, 5590\u20135602. https:\/\/doi.org\/10.1002\/cam4.5409 (2023).","journal-title":"Cancer Med."},{"key":"41978_CR21","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/blood-2024-206063","volume":"144","author":"T Yin","year":"2024","unstructured":"Yin, T. et al. VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations. Blood 144, 4100 (2024).","journal-title":"Blood"},{"key":"41978_CR22","doi-asserted-by":"publisher","unstructured":"Pagliuca, S. et al. Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms232314885 (2022).","DOI":"10.3390\/ijms232314885"},{"key":"41978_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.4062\/biomolther.2024.017","volume":"32","author":"K Ai","year":"2024","unstructured":"Ai, K. et al. Inhibition of Tumoral VISTA to Overcome TKI Resistance via Downregulation of the AKT\/mTOR and JAK2\/STAT5 Pathways in Chronic Myeloid Leukemia. Biomol. Ther. (Seoul). 32, 582\u2013600. https:\/\/doi.org\/10.4062\/biomolther.2024.017 (2024).","journal-title":"Biomol. Ther. (Seoul)"},{"key":"41978_CR24","doi-asserted-by":"publisher","first-page":"1907059","DOI":"10.1080\/2162402x.2021.1907059","volume":"10","author":"HX He","year":"2021","unstructured":"He, H. X. et al. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer\/T-cell lymphoma. Oncoimmunology 10, 1907059. https:\/\/doi.org\/10.1080\/2162402x.2021.1907059 (2021).","journal-title":"Oncoimmunology"},{"key":"41978_CR25","doi-asserted-by":"publisher","first-page":"1466839","DOI":"10.3389\/fimmu.2024.1466839","volume":"15","author":"Y Duan","year":"2024","unstructured":"Duan, Y. et al. VISTA in hematological malignancies: a review of the literature. Front. Immunol. 15, 1466839. https:\/\/doi.org\/10.3389\/fimmu.2024.1466839 (2024).","journal-title":"Front. Immunol."},{"key":"41978_CR26","doi-asserted-by":"publisher","first-page":"19107","DOI":"10.1038\/s41598-023-46552-8","volume":"13","author":"CZ Wang","year":"2023","unstructured":"Wang, C. Z. et al. Comprehensive characterization of TGFB1 across hematological malignancies. Sci. Rep. 13, 19107. https:\/\/doi.org\/10.1038\/s41598-023-46552-8 (2023).","journal-title":"Sci. Rep."},{"key":"41978_CR27","doi-asserted-by":"publisher","first-page":"1477100","DOI":"10.3389\/fimmu.2025.1477100","volume":"16","author":"XM Wen","year":"2025","unstructured":"Wen, X. M. et al. Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity. Front. Immunol. 16, 1477100. https:\/\/doi.org\/10.3389\/fimmu.2025.1477100 (2025).","journal-title":"Front. Immunol."},{"key":"41978_CR28","doi-asserted-by":"publisher","first-page":"1569641","DOI":"10.3389\/fimmu.2025.1569641","volume":"16","author":"XM Wen","year":"2025","unstructured":"Wen, X. M. et al. FOXP1 is associated with oncogenesis and clinical outcomes in hematologic malignancies. Front. Immunol. 16, 1569641. https:\/\/doi.org\/10.3389\/fimmu.2025.1569641 (2025).","journal-title":"Front. Immunol."},{"key":"41978_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.omto.2022.05.011","volume":"26","author":"ZJ Xu","year":"2022","unstructured":"Xu, Z. J. et al. Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia. Mol. therapy oncolytics. 26, 88\u2013104. https:\/\/doi.org\/10.1016\/j.omto.2022.05.011 (2022).","journal-title":"Mol. therapy oncolytics"},{"key":"41978_CR30","doi-asserted-by":"publisher","first-page":"7831","DOI":"10.1002\/cam4.4284","volume":"10","author":"LY Zhang","year":"2021","unstructured":"Zhang, L. Y. et al. Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia. Cancer Med. 10, 7831\u20137846. https:\/\/doi.org\/10.1002\/cam4.4284 (2021).","journal-title":"Cancer Med."},{"key":"41978_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4905","author":"ZJ Xu","year":"2022","unstructured":"Xu, Z. J. et al. Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.4905 (2022).","journal-title":"Cancer Med."},{"key":"41978_CR32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/blood.2022016033","volume":"140","author":"MH Kramer","year":"2022","unstructured":"Kramer, M. H. et al. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia. Blood 140, 1533\u20131548. https:\/\/doi.org\/10.1182\/blood.2022016033 (2022).","journal-title":"Blood"},{"key":"41978_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41419-020-03213-2","volume":"11","author":"JD Zhou","year":"2020","unstructured":"Zhou, J. D. et al. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes. Cell Death Dis. 11, 997. https:\/\/doi.org\/10.1038\/s41419-020-03213-2 (2020).","journal-title":"Cell Death Dis."},{"key":"41978_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell 176, 1265\u20131281e1224. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031 (2019).","journal-title":"Cell"},{"key":"41978_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer cell. 39, 845\u2013865e847. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.014 (2021).","journal-title":"Cancer cell."},{"key":"41978_CR36","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199. https:\/\/doi.org\/10.1056\/NEJMoa1406498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"41978_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/2326-6066.Cir-16-0019","volume":"5","author":"T Nathanson","year":"2017","unstructured":"Nathanson, T. et al. Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunol. Res. 5, 84\u201391. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0019 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"41978_CR38","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927. https:\/\/doi.org\/10.1038\/s41591-019-0654-5 (2019).","journal-title":"Nat. Med."},{"key":"41978_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy. Cancer cell. 35, 238\u2013255e236. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003 (2019).","journal-title":"Cancer cell."},{"key":"41978_CR40","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat. cancer. 2, 1124\u20131135. https:\/\/doi.org\/10.1038\/s43018-021-00269-7 (2021).","journal-title":"Nat. cancer"},{"key":"41978_CR41","doi-asserted-by":"publisher","first-page":"1683347","DOI":"10.1080\/2162402x.2019.1683347","volume":"9","author":"ZJ Xu","year":"2020","unstructured":"Xu, Z. J. et al. The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology 9, 1683347. https:\/\/doi.org\/10.1080\/2162402x.2019.1683347 (2020).","journal-title":"Oncoimmunology"},{"key":"41978_CR42","doi-asserted-by":"publisher","first-page":"eadi7418","DOI":"10.1126\/sciimmunol.adi7418","volume":"9","author":"HM Ta","year":"2024","unstructured":"Ta, H. M. et al. LRIG1 engages ligand VISTA and impairs tumor-specific CD8(+) T cell responses. Sci. Immunol. 9, eadi7418. https:\/\/doi.org\/10.1126\/sciimmunol.adi7418 (2024).","journal-title":"Sci. Immunol."},{"key":"41978_CR43","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/2159-8290.Cd-22-0366","volume":"13","author":"HJ Uckelmann","year":"2023","unstructured":"Uckelmann, H. J. et al. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia. Cancer Discov. 13, 746\u2013765. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0366 (2023).","journal-title":"Cancer Discov."},{"key":"41978_CR44","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.Cd-22-0424","volume":"13","author":"XQD Wang","year":"2023","unstructured":"Wang, X. Q. D. et al. Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia. Cancer Discov. 13, 724\u2013745. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0424 (2023).","journal-title":"Cancer Discov."},{"key":"41978_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai, F. et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122, 749\u2013758. https:\/\/doi.org\/10.1182\/blood-2013-01-480129 (2013).","journal-title":"Blood"},{"key":"41978_CR46","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920\u2013924. https:\/\/doi.org\/10.1038\/s41586-023-05812-3 (2023).","journal-title":"Nature"},{"key":"41978_CR47","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer. 7, 823\u2013833. https:\/\/doi.org\/10.1038\/nrc2253 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"41978_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa, G. C. et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J. Clin. oncology: official J. Am. Soc. Clin. Oncol. 43, 75\u201384. https:\/\/doi.org\/10.1200\/jco.24.00826 (2025).","journal-title":"J. Clin. oncology: official J. Am. Soc. Clin. Oncol."},{"key":"41978_CR49","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","volume":"15","author":"T Thisted","year":"2024","unstructured":"Thisted, T. et al. VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nat. Commun. 15, 2917. https:\/\/doi.org\/10.1038\/s41467-024-47256-x (2024).","journal-title":"Nat. Commun."},{"key":"41978_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2326-6066.Cir-22-0116","volume":"11","author":"E Schaafsma","year":"2023","unstructured":"Schaafsma, E. et al. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. Cancer Immunol. Res. 11, 38\u201355. https:\/\/doi.org\/10.1158\/2326-6066.Cir-22-0116 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"41978_CR51","doi-asserted-by":"publisher","first-page":"1225081","DOI":"10.3389\/fonc.2023.1225081","volume":"13","author":"RJ Noelle","year":"2023","unstructured":"Noelle, R. J. et al. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Front. Oncol. 13, 1225081. https:\/\/doi.org\/10.3389\/fonc.2023.1225081 (2023).","journal-title":"Front. Oncol."},{"key":"41978_CR52","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner, F. et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913\u2013919. https:\/\/doi.org\/10.1038\/s41586-023-05755-9 (2023).","journal-title":"Nature"},{"key":"41978_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","volume":"42","author":"L Yuan","year":"2021","unstructured":"Yuan, L., Tatineni, J., Mahoney, K. M., Freeman, G. J. & VISTA A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends Immunol. 42, 209\u2013227. https:\/\/doi.org\/10.1016\/j.it.2020.12.008 (2021).","journal-title":"Trends Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41978-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41978-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41978-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:14:31Z","timestamp":1775556871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41978-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41978"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41978-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of the Affiliated People\u2019s Hospital of Jiangsu University (Approval No. K-20230212-Y). Written informed consent was obtained from all participants or their legal guardians prior to sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"11556"}}